Schering, Mylan Settle Generic Clarinex Patent Case

By Jocelyn Allison

Law360, New York (April 08, 2009, 12:00 AM ET) -- Mylan Pharmaceuticals Inc. and Schering Corp. have reached an agreement in patent litigation over Clarinex that will allow the generics maker to begin selling a copycat version of the allergy medicine in July 2012.

The agreement allowing Mylan to make desloratadine in 5 mg tablets resolves all claims pending between the two pharmaceutical rivals in the U.S. District Court for the District of New Jersey, the companies said Wednesday.

Mylan will have the right to market the tablets in the U.S. on July 1, 2012, or...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles